Paliperidone Palmitate

Antipsychotics differed in their efficacy in preventing relapse hospitalization and treatment failure among patients with schizophrenia spectrum disorder, according to research published in JAMA Network Open.

Paliperidone palmitate appeared to benefit Black patients with recent-onset schizophrenia or schizophreniform disorder, according to study results presented at NEI Congress.

Long-acting injectable formulations of paliperidone, aripiprazole and olanzapine had the highest effect sizes and certainty of evidence for relapse prevention and acceptability, researchers noted in American Journal of Psychiatry.

Long-acting injectable paliperidone use was associated with significant improvement in clinical and functional outcomes among individuals with schizophrenia, according to study results published in Journal of Clinical Psychiatry.

Aristada Initio and Invega Sustenna appeared well tolerated and effective for initiating in-hospital schizophrenia treatment and continuing outpatient treatment, according to a study published in Journal of Clinical Psychiatry.